Biogen/ Ionis ALS therapy set for March FDA AdCom meeting

The FDA announced that a panel of experts is scheduled to meet on Mar. 22 to discuss the marketing application for tofersen, a treatment for neurodegenerative disorder amyotrophic lateral sclerosis (ALS) developed by Biogen (NASDAQ:BIIB) and Ionis Pharma (NASDAQ:IONS).